Eisai (OTCMKTS:ESALY – Get Rating) issued an update on its FY 2023 earnings guidance on Monday morning. The company provided earnings per share guidance of $1.38-$1.38 for the period. The company issued revenue guidance of $5.32 billion-$5.32 billion.
Eisai Price Performance
Shares of OTCMKTS ESALY opened at $65.96 on Wednesday. Eisai has a fifty-two week low of $36.88 and a fifty-two week high of $68.00. The stock has a market cap of $18.92 billion, a price-to-earnings ratio of 72.98, a PEG ratio of 3.50 and a beta of 0.25. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.71 and a current ratio of 2.06. The firm’s 50-day simple moving average is $54.68 and its 200 day simple moving average is $46.89.
Analyst Ratings Changes
Separately, Morgan Stanley raised shares of Eisai from an underweight rating to an equal weight rating in a research report on Wednesday, September 28th.
Eisai Company Profile
Eisai Co, Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures.
- Get a free copy of the StockNews.com research report on Eisai (ESALY)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.